© 2001 by European Society of Cardiology
EDITORIAL
A Prophylactic ICD? Who are the patients? What is the device?
Guidant Corporation, European Headquaters Diegan, Belgium
Key Words: Implantable cardioverter defibrillator (ICD), sudden death, primary prevention, cost-effectiveness
Correspondence: Seah Nisam, Guidant Corporation, Park Lane Culliganlaan 2b, Diegem 1831, Belgium. E-mail: snisam{at}guidant.com
References
[1] Böcker D, Block M, Borggrefe M, Breithardt G. Defibrillators are superior to antiarrhythmic drugs in the treatment of ventricular tachyarrhythmias. Eur Heart J 1997; 18: 26–30.
[2] Naccarelli G, Wolbrette D, Dell'orfano J, et al. A decade of clinical trial developments in postmyocardial infarction, congestive heart failure and sustained ventricular tachyarrhythmias patients: From CAST to AVID and beyond. J Cardiovasc Electrophysiol 0000; 9: 864–891.
[3] Cannom D and Prystowsky E. Management of ventricular arrhythmias: detection, drugs and devices. JAMA 1999; 281: 172–179.
[4] Domanski M, Saksena S, Epstein A, et al. Relative effectiveness of the implantable cardioverter defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias: AVID Investigations. J Am Coll Cardiol 1999; 34: 1090–1095.
[5] Owens D, Sanders G, Harris R, et al. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. Ann Intern Med 1997; 126: 1–12.
[6] Stanton M and Bell G. Economic outcomes of implantable cardioverter-defibrillators. Circulation 2000; 101: 1067–1074.
[7] Moss A, Hall J, Cannom D, et al. Improved Survival with an Implanted Defibrillator in Patients with Coronary Disease at High Risk of Ventricular Arrhythmias. N Engl J Med 1996; 335: 1933–1940.
[8] Buxton A, Lee K, Fisher J, Josephson M, Prystowsky E, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999; 341: 1882–1890.
[9] Klein H, Auricchio A, Reek S, Geller C. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction. SCD-Heft and MADIT-2. Am J Cardiol 1999; 83: 91D–97D.[CrossRef][Web of Science][Medline]
[10] McDonald K and Hlatky M. Cost reduction and implantable cardioverter defibrillation. J Cardiovasc Electrophysiol 2001; 12: 167–168.[CrossRef][Web of Science][Medline]
[11] Zipes D. Implantable cardioverter defibrillator: a Volkswagen or a Rolls-Royce: How much will we pay to save a life? Circulation 2000; 103: 1372–1374.
[12] Nisam S and Mower M. ICD Trials: an extraordinary means of determining patient risk? Pacing Clin Electrophysiol 1998; 21: 1341–1346.[CrossRef][Medline]
[13] Camm AJ and Nisam S. The utilization of the implantable defibrillator — a European Enigma. Eur Heart J 2000; 21: 1998–2004.
[14] The Antiarrhythmic vs Implantable Defibrillator (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997; 337: 1576–1583.
[15] Kim S, Hallstrom A, Love J, et al. Comparison of clinical characteristics and frequency of implantable defibrillator use between randomized patients in the AVID trial and non-randomized Registry patients. Am J Cardiol 1997; 80: 454–457.[CrossRef][Web of Science][Medline]
[16] Fogoros R, Elson J, Bonnet C. Survival of patients who have received appropriate shocks from their implantable defibrillators. Pacing Clin Electrophysiol 1991; 14: 1842–1845.[CrossRef][Medline]
[17] Higgins S, Klein H, Nisam S. Which device should ‘MADIT protocol’ patients receive? Am J Cardiol 1997; 79: 31–35.[Medline]
[18] Böcker D, Bänsch D, Heinecke A, et al. Potential benefit from implantable cardioverter-defibrillator therapy in patients with and without heart failure. Circulation 1998; 98: 1636–1643.
[19] Villacastin J, Almendral J, Arenal A, et al. Incidence and clinical significance of multiple consecutive, appropriate high-energy discharges in patients with implanted cardioverter-defibrillators. Circulation 1996; 93: 753–762.
[20] Exner D, Pinski S, Wyse G, et al. Electrical storm presages nonsudden death. Circulation 2001; 103: 2066–2071.
[21] Grom A, Baron T, Faber T, et al. Clusters of life-threatening ventricular arrhythmias in patients with implanted cardioverter-defibrillators: prevalence, characteristics, and risk stratification. Clin Cardiol 2001; 24: 330–333.[Web of Science][Medline]
[22] Bänsch D, Böcker D, Brunn J, et al. Clusters of ventricular tachycardias signify impaired survival in patients with idiopathic dilated cardiomyopathy and implantable cardioverter defibrillators. J Am Coll Cardiol 2000; 36: 566–573.
[23] Nunain S, Roelke M, Trouton T, et al. Limitations and late complications of third generation automatic cardioverter-defibrillators. Circulation 1995; 91: 2204–2213.
[24] Weber M, Block M, Brunn J, et al. Inappropriate ICD therapies: incidence, causes, risk factors and prevention. Z Kardiol 1996; 85: 809–819.[Web of Science][Medline]
[25] Rosenqvist M, Beyers T, Block M, et al. Adverse events with transvenous implantable cardioverter-defibrillators: a prospective multicenter study. Circulation 1998; 98: 668–670.
[26] Heisel A, Neuzner J, Himmrich E, et al. Safety of antitachycardia pacing in patients with implantable cardioverter defibrillators and severely depressed left ventricular function. Pacing Clin Electrophysiol 1995; 18: 137–141.[CrossRef][Medline]
[27] Schaumann A, Von zur Mühlen G, Herse B, et al. Empirical vs tested antitachycardia pacing in implantable cardioverter defibrillators. A prospective study including 200 patients. Circulation 1998; 97: 66–74.
[28] Neuzner J, Pitschner H, Schlepper M. Programmable VT detection enhancements in implantable cardioverter defibrillator therapy. Pacing Clin Electrophysiol 1995; 18: 539–547.[CrossRef][Medline]
[29] Rüppel R, Schlüter C, Boczor S, et al. Ventricular tachycardia during follow-up in patients resuscitated from ventricular fibrillation: experience from stored electrograms of implantable cardioverter-defibrillators. J Am Coll Cardiol 1998; 32: 1724–1730.
[30] Ousdigian K, Gillberg J, Koehler J, et al. How often is ICD-detected VF actually monomorphic VT? Pacing Clin Electrophysiol 2001; 24: 731 (Abstract).
[31] Leitch J, Gillis A, Wyse G, et al. Reduction in defibrillator shocks with an implantable device combining antitachycardia pacing and shock therapy. J Am Coll Cardiol 1991; 18: 145–151.[Abstract]
[32] Block M and Breithardt G. Implantable cardioverter-defibrillators: clinical aspects. In Zipes D and Jalife J (Eds.). Cardiac Electrophysiology: From Cell to Bedside 1999; Philadelphia Saunders pp. 958–970.
[33] Lüderitz B, Jung W, Deister A, et al. Patient acceptance of the implantable cardioverter defibrillator in ventricular tachyarrhythmias. Pacing Clin Electrophysiol 1993; 16: 1815–1821.[CrossRef][Medline]
[34] Schaumann A, von zur Mühlen F, Gonska B, Kreuzer H. Enhanced detection criteria in implantable cardioverter-defibrillators to avoid inappropriate therapy. Am J Cardiol 1996; 78: 42–50.[Web of Science][Medline]
[35] Brugada J, Mont L, Figueiredo M, et al. Enhanced detection criteria in implantable defibrillators. J Cardiovasc Electrophysiol 1998; 9: 261–268.[Web of Science][Medline]
[36] Hook B, Callans D, Kleiman R, et al. Implantable cardioverter-defibrillator therapy in the absence of significant symptoms. Rhythm diagnosis and management aided by stored electrogram analysis. Circulation 1993; 87: 1897–1906.
[37] Auricchio A, Hartung W, Geller C, Klein H. Clinical relevance of stored electrograms for implantable cardioverter-defibrillator troubleshooting and understanding of mechanisms for ventricular tachyarrhythmias. Am J Cardiol 1996; 78: 33–41.[CrossRef][Web of Science][Medline]
[38] Smith P, Vidaillet H, Hayes J, et al. Infections with non-thoracotomy implantable cardioverter defibrillators: can these be prevented? Pacing Clin Electrophysiol 1998; 21: 42–55.[CrossRef][Medline]
[39] Brugada P, Brugada R, Brugada J, Geelen P. Use of the prophylactic implantable cardioverter defibrillator for patients with normal hearts. Am J Cardiol 1999; 83: 98–100.[Web of Science][Medline]
[40] Nademane K, Veerali G, Nimmannit S, et al. Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. Circulation 1997; 96: 2595–2600.
[41] Zarebo W, Moss A, Schwartz P, et al. Influence of the genotype on the clinical course of the long QT syndrome. N Engl J Med 1998; 339: 960–965.
[43] Winkle R, Mead H, Ruder M, et al. Long-term outcome with the automatic implantable cardioverter defibrillator. J Am Coll Cardiol 1989; 13: 1353–1361.[Abstract]
[44] Pitschner H, Neuzner J, Himmrich E, Liebrich A, Jung J, Heisel A. Implantable cardioverter-defibrillator therapy: influence of left ventricular function on long-term results. J Intervent Card Electrophysiol 1997; 1: 211–220.[CrossRef][Medline]
[45] Wever E, Hauer R, Van Capelle F, et al. Randomized study of implantable defibrillator as first-choice therapy vs conventional strategy in postinfarct sudden death survivors. Circulation 1995; 91: 2195–2203.
[46] Fogors R, Elson J, Bonnet C. Actuarial incidence and pattern of occurrence of shocks following implantation of the automatic implantable cardioverter defibrillator. Pacing Clin Electrophysiol 1989; 12: 1465–1473.[CrossRef][Medline]
CiteULike 
Connotea 
Del.icio.us What's this?
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||